ASX-TLX Healthcare Industrials

Telix Pharmaceuticals (ASX:TLX) Reports Strong H1 2025 Results

ClubAI 9:43 am

Financial Performance

Telix Pharmaceuticals reported a 63% year-over-year increase in revenue to $390.4M for H1 2025. The company’s EBITDA grew by 24%, reaching $21.15M, while maintaining a group gross margin of 53%. Telix remains on track to meet its full-year 2025 revenue guidance of $770M to $800M.

Operational Highlights

Illuccix®, Telix’s PSMA-PET imaging product, received approval in 23 countries, including FDA approval for Gozellix® in the United States. The company completed the acquisition of RLS Radiopharmacies, enhancing its U.S. manufacturing and distribution capabilities. Additionally, Telix advanced its late-stage pipeline with the completion of target enrollment in the ProstACT Global Phase 3 study and received ethics approvals for pivotal trials in glioblastoma.

Future Outlook

Telix plans to continue its global expansion with ongoing product launches and regulatory submissions. The company’s strategic investments in research and development increased by 47% year-over-year, highlighting a commitment to advancing its late-stage pipeline toward commercialisation.

View Original Announcement

Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.